FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:660-662 September 7, 1995 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

The first decade of orthotopic heart transplantation featured the perfection of the surgical techniques, the use of immunosuppressive drugs, and the introduction of endomyocardial biopsy. Improved survival rates of 85 percent and 70 percent after one and five years, respectively, during the second decade of transplantation were directly attributable to cyclosporine, which reduced mortality from infectious complications. Despite this progress, rejection and infection remain the most important predictors of mortality during the first year after transplantation, and accelerated coronary artery disease is the chief impediment to long-term survival.¹ Two socioeconomic matters — limited supplies of organs and costs — are . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Vassalli, G., Fleury, S., Li, J., Goy, J.-J., Kappenberger, L., von Segesser, L. K. (2003). Gene transfer of cytoprotective and immunomodulatory molecules for prevention of cardiac allograft rejection. Eur. J. Cardiothorac. Surg. 24: 794-806 [Abstract] [Full Text]  
• Vassalli, G., Gallino, A., Weis, M., von Scheidt, W., Kappenberger, L., von Segesser, L.K., Goy, J.-J., on behalf of the Working Group Microcirculation of, (2003). Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy. Eur Heart J 24: 1180-1188 [Abstract] [Full Text]  
• Schoen, F. J., Padera, R. F. Jr. (2003). Cardiac Surgical Pathology. Card Surg Adult 2: 119-185 [Full Text]  
• Wolthers, T., Hoffman, D. M., Nugent, A. G., Duncan, M. W, Umpleby, M., Ho, K. K. Y. (2001). Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women. Am. J. Physiol. Endocrinol. Metab. 281: E1191-E1196 [Abstract] [Full Text]  
• Ballantyne, C. M., von Moltke, L. L., Greenblatt, D. J., Kobashigawa, J., Keogh, A. M., Spratt, P., Valantine, H. A. (1996). Drugs in Cardiac Transplantation. NEJM 334: 400-402 [Full Text]